Donaldson Company (DCI) The 44th Annual William Blair Growth Stock Conference summary
Event summary combining transcript, slides, and related documents.
The 44th Annual William Blair Growth Stock Conference summary
1 Feb, 2026Key messages and strategic direction
Emphasizes technology leadership and complex problem-solving in filtration, with a shift from geographic to vertical segment orientation for faster growth.
Focus on sustainability, enabling the green economy, and a balanced approach to organic and inorganic growth.
Life Sciences identified as a new vertical, with significant recent acquisitions and disruptive technologies.
Company has a global presence, with 75% of volume built within regional markets to offset supply chain risks.
Record financial performance, including record sales, operating margin, and EPS, with a 10% CAGR over three years.
Technology, innovation, and competitive advantages
Over 2,700 patents released from 2019 to 2023, highlighting a strong commitment to R&D and innovation.
Proprietary technologies enable solutions like 99% acetonitrile reclamation, supporting customer sustainability goals.
Deep customer relationships and diversified product applications, from medical devices to industrial engines.
High aftermarket retention, with 65% of business from replacement parts and 60 manufacturing plants worldwide.
Leadership in alternative power solutions and fuel cell programs, leveraging cross-segment technology expertise.
Segment growth and market opportunities
Mobile Solutions segment focuses on non-passenger vehicle markets, with confidence in long-term growth despite slow alternative power adoption.
Industrial segment strategy includes connected solutions, driving double-digit aftermarket growth and data-driven innovation.
Life Sciences segment expanded by $21 billion in addressable market through four recent acquisitions, including Medica for hollow fiber membranes.
Food and beverage business growing, with bioreactors enabling cultivated meat partnerships and medical device filter leadership.
Ongoing R&D in implantable medical devices and advanced filtration materials like expanded Teflon.
Latest events from Donaldson Company
- Record sales and margin growth driven by innovation, global reach, and strategic acquisitions.DCI
47th Annual Raymond James Institutional Investor Conference4 Mar 2026 - Q2 sales up 3% to $896M, flat EPS, and $820M Facet acquisition to boost future margins.DCI
Q2 202626 Feb 2026 - Record results and strong outlook driven by aftermarket growth, technology, and disciplined capital strategy.DCI
Morgan Stanley’s 13th Annual Laguna Conference3 Feb 2026 - Record Q3 sales, margin expansion, and raised EPS guidance highlight robust growth.DCI
Q3 202431 Jan 2026 - Proprietary technology, global expansion, and strategic investments drive growth and resilience.DCI
Stifel 2024 Cross Sector Insight Conference31 Jan 2026 - Record sales, margin expansion, and robust Aftermarket growth drive FY24 earnings higher.DCI
Q4 202423 Jan 2026 - Technology-driven growth, digitalization, and Life Sciences expansion fuel strong financial outlook.DCI
Jefferies Global Industrial Conference 202422 Jan 2026 - Technology-driven growth, M&A, and aftermarket strength fuel margin and share gains.DCI
Morgan Stanley‘s 12th Annual Laguna Conference 202420 Jan 2026 - Record sales, margin growth, and Life Sciences expansion drive future-focused strategy.DCI
CL King's 22nd Annual Best Ideas Conference 202420 Jan 2026